Periprosthetic Joint Infection
Conditions
Keywords
Ankle-related Infections
Brief summary
This study is being conducted to evaluate the safety and effectiveness of the REMEDY SPECTRUM IM Spacer Nail in the treatment of ankle-related infections. The study is expected to take approximately 18 months from first subject enrolled to the last follow-up visit. It will have a 12-month enrollment period and a 6-month follow-up. This study is a Prospective, multicenter, single-arm clinical trial. All subjects enrolled in this study will receive the REMEDY SPECTRUM IM Spacer Nail.
Interventions
COMBINATION_PRODUCTREMEDY Spectrum IM Spacer Nail
The REMEDY SPECTRUM IM Spacer Nail is a single-use implant made of polymethylmethacrylate (PMMA) which is internally reinforced with a stainless-steel core (ASTM F138, ISO 5832-1). The PMMA of the REMEDY SPECTRUM IM Spacer Nail is laden with gentamicin and vancomycin. The nail has a slot at the distal end and can be combined with the surgeon's choice of fixation to prevent migration depending on the anatomy of the patient. The REMEDY SPECTRUM IM Spacer Nail is available in two lengths (150mm and 300mm) to accommodate variations in patient anatomy. The distal end has a threaded recess for mating with the optional distal cap, as well as the insertion and removal tools.
Sponsors
OsteoRemedies, LLC
MCRA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Be ≥ 21 years of age 2. Have an ankle-related infection 3. Is skeletally mature, as evidenced by closed epiphyses. 4. Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study 5. Be willing and able to comply with all study procedures including all pre-operative, post-operative requirements 6. If female and of child-bearing potential, must have a negative pregnancy test prior to the surgical procedure and no intention of becoming pregnant until study completion.
Exclusion criteria
1. Infections that do not involve the ankle 2. Have a known immunodeficiency; including subjects who are receiving or have received immunosuppressants, immunostimulating agents or radiation therapy within 6 months prior to surgery 3. Affected limb is dysvascular 4. Where adequate soft-tissue coverage cannot be achieved 5. Have any mental or psychological disorder that would impair their ability to complete the study questionnaires 6. Are currently pregnant or breastfeeding, or planning to become pregnant or breastfeed any time during the course of the study 7. Are currently a prisoner 8. Have any medical condition or other circumstances, in the judgment of the Investigator, that might interfere with the ability to return for follow-up visits, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate post-operative activities. 9. History of vancomycin or gentamicin allergy 10. Are implanted with other antibiotic eluting products.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Successful Treatment of Infection Based on Lab Values and Culture | 6 months | Healed wound and no infection recurrence caused by the same organism strain infection for duration of two weeks post antibiotic regimen. |
Countries
United States
Contacts
CONTACTCrystal Djaba
CONTACTJacob Schafer
STUDY_DIRECTORRachel McGuire Kennedy
OsteoRemedies, LLC
Outcome results
None listed